1 / 64

HIV

HIV. The Human immunodeficiency virus. Retrovirus RNA virus Protein coat (HIV antigens) Reverse transcriptase turn RNA into DNA HIV integrase incorporates viral DNA into host genome Transcribed by host/viral enzymes Viral assembly and shedding with protease. Pathophysiology.

quon-cash
Télécharger la présentation

HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV

  2. The Human immunodeficiency virus • Retrovirus • RNA virus • Protein coat (HIV antigens) • Reverse transcriptase turn RNA into DNA • HIV integrase incorporates viral DNA into host genome • Transcribed by host/viral enzymes • Viral assembly and shedding with protease

  3. Pathophysiology Transmission : - sexual - nonsexual

  4. Categorization of HIV exposures • Group 1 HIV antibody positive – asymptomatic • Group 2 ARC, CD4 < 400 symptoms (fever, malaise, lymphadenopathy, diarrhea), opportunistic infections

  5. Categorization of HIV exposures • Group 3 AIDS; CD4 < 200 Kaposi’s sarcoma, lymphoma, pneumonia, cervical carcinoma, etc.

  6. Signs and symptoms • Initial exposure or infection • Flulike symptoms-fever, weakness, 10 to 14 days • Asymptomatic stage • serologic evidence of infection • no signs or symptoms

  7. Signs and symptoms • Symptomatic stage • serologic evidence of infection • T4/T8 ratio reduced to about 1 • persistent lymphadenopathy • oral candidiasis • constitutional symptoms : night sweats, diarrhea, weight loss, fever malaise, weakness

  8. Signs and symptoms • Advanced symptomatic stage • serologic evidence of infection • T4/T8 ratio < 0.5 • HIV encephalopathy • HIV wasting syndrome • major opportunistic infections • Neoplasms : kaposi’s sarcoma, lymphoma

  9. Laboratory • blood, semen, breast milk, tears, saliva • With or without clinical : antibodies • Advanced HIV : • altered ratio T4/T8 • decreased total number of lymphocytes • trombocytopenia, anemia • alteration in Ab system • Cutaneous anergy

  10. Laboratory test • ELISA : sensitive, high rate of false positive screen • Second test : Western blot • Combination of test : > 99% accurate • Positive : exposed to AIDS virus potentially infectious • PCR

  11. Laboratory test • Status and potential risk of surgery • Viral load • CD4 lymphocyte count

  12. Laboratory test • Viral load • Current viral activity • Disease progression • > 30,000 – 50,000 HIV RNA copies/ml plasma poor prognosis • < 5000 HIV RNA copies/ml plasma better short-term prognosis

  13. Laboratory test • CD4 lymphocyte • Degree of immunologic destruction AIDS : • low lymphocyte count and • depressed CD4 T-cells • CD4 : CD8 ratio of 1:0 or less

  14. Opportunistic infection • Pneumocystis carinii pneumonia (PCP) • Protozoan parasite • Invade lungs (rarely LN) • Symptoms : fever, cough, difficulty breathing, weight loss, night sweats, fatigue • Prophylaxis : TMP-SMX,

  15. Opportunistic infection • Toxoplasmosis • Protozoa • Infection of CNS • Symptoms : neurologic headaches, dizziness, seizures

  16. Opportunistic infection • Cryptosporidiosis • Protozoa • Affect GI tract Nausea, vomiting, diarrhea, malaise, fever, weight loss

  17. Opportunistic infection • Candidiasis • Oral and systemic • Infect mucous membrane : mouth, vagina, esophagus, GI tract, skin • Systemic Tx. Fluconazole or ketoconazole

  18. Opportunistic infection • Cryptococcus and histoplasma • Yeastlike fungi • Infect lung and brain, other tissue • Fever, weight loss, neurologic symptoms, difficulty breathing, mucosal lesion, headache, N/V, malaise • Tx. : fluconazole, ketoconazole, amphotericin B

  19. Opportunistic infection • Tuberculosis • Mycobacterium tubercullosis • S/S : lymphadenopathy, cough, fever weight loss, diarrhea, night sweats, malaise • Skin test • Tx : Isoniazid (INH), Rifampin, ethambutol, streptomycin

  20. Opportunistic infection • Tuberculosis • Multiantibioticresistant form of TB • Mycobacterium avium • Mycobacterium intracellulare • Tx. : ciprofloxacin, amikacin sulfate, ethambutol

  21. Opportunistic infection • Cytomegalovirus • 90% of HIV • Oral cavity : deep, non-healing ulcerations • Retinitis • Esophagitis • Colitis • Tx. : Ganciclovir

  22. Opportunistic infection • Herpes simplex/ herpes zoster • Infect epithelial tissue and nerve ending • Symptoms: painful inflammatory blisters follow a sensory nerve tract • Tx./prophylaxis : acyclovir

  23. Opportunistic infection • Epstein-Barr virus • Associated with oral hairy leukoplakia in HIV/AIDS • Acyclovir or ganciclovir

  24. Opportunistic infection • Human papillomavirus • Oral cavity • Clinical : oral warts • Tx. excision

  25. HAART therapy • Highly Active Anti-Retroviral Therapy • Is essentially triple (or even quadruple therapy) • Two nucleoside reverse transcriptase inhibitors (NRTIs) combined with either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)

  26. Nucleoside reverse transcriptase inhibitors(NRTIs) • Zidovudine AZT • Dideoxyinosine DDI • Dideoxycytidine DDC • Stavudine d4T • Lamivudine 3TC • Etc.

  27. Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) • Delavirdine DLV • Efavirenz EFV • Nevirapine NVP • Copravirine CPV • Etc.

  28. Protease inhibitors (PIs) • Affect s posttranslational modification (late stage) of HIV replication • Ritonavir RTV • Indinavir IDV • Amprenavir APV • Etc.

  29. Entry inhibitors (or fusion inhibitors) • Block viral entry into cells Fuzeon (enfuvirtide, T-20)

  30. Goal of therapy • Maximal and durable suppression of viral load in blood • Restoration and/or preservation of immunological function • Reduction of HIV-related morbidity and mortality

  31. Thailand GPO-vir • This is a generic drug combination of • d4T (stavudine) • 3TC (lamivudine) • NVP (nevirapine)

  32. Side effects • anemia : major (toxic to bone marrow and blood cellls) blood transfusion in severe case • leukopenia and granulocytopenia : predispose to infections, fatigue, muscle pain, rashes, nausea, diarrhea and headaches • hepatotoxicity, peripheral neuropathy and pancreatitis

  33. Side effects (oro-facial) • Taste perversion • Ritinovir (PI) • Circumoral paresthesia • Amprenivir (PI) • Ritinovir (PI) • Stevens johnson syndrome (EM) • Neviripine (NNRTI) • Amprenivir (PI)

  34. Side effects (oro-facial) • Stomatitis, oral ulceration • Abacavir (NRTI) • Thrombocytopenia, anemia • Indinavir (PI) • zidovudine (NRTI) • Parotid swelling (lipomatosis) • Protease inhibitor • Xerostomia • DDI • Protease inhibitors

  35. Treatment planning • Current CD4 lymphocyte count • Viral load • Presence and status of opportunistic infections • Medications

  36. Dental Treatment • Exposed to AIDS virus, HIV seropositive but asymptomatic, ARC : CD4> 400 receive all indicated dental Tx.

  37. Dental Treatment • Symptomatic , early stage of AIDS (CD4< 200) : increased susceptibility to opportunistic infections prophylactic drugs receive most dental care (after R/O neutropenia, thrombocytopenia) Complex Tx. : prognosis of medical condition

  38. Treatment planning • Medicated with drug, prophylactic for opportunistic infection allergic reaction, toxic drug reaction, hepatotoxicity, immunosuppression, anemia, serious drug interaction • Consultation, investigation (bleeding time, WBC)

  39. Dental management severe thrombocytopenia platelet replacement before surgery • Prophylactic antibiotics : severe immune neutropenia (< 500 cells/mm) • In general , only urgent Tx. needs for patient with advanced AIDS

  40. Drug interaction • Acetaminophen : caution with AZT (granulocytopenia, anemia may be intensified) • Aspirin : avoid in thrombocytopenia • Antacids, phenytoin, cimetidine, rifampin : avoid in ketoconazole (altered absorption and metabolism)

  41. Cerebrovascular accident

  42. Stroke (CVA, apoplexy) • Serious, often fatal • cerebrovascular disease • Not fatal : some degree debilitated in motor function, speech or mentation

  43. Stroke : generic name neurologic deficit sudden interruption of oxygenated bl to brain focal necrosis of brain tissue

  44. Interruption of blood supply : • Occlusive - thrombosis of cerebral vessel (65%-80%) - cerebral embolism • hemorrhage - intracranial hemorrhage

  45. Cerebrovascular disease • Atherosclerosis (most common) • hypertensive vascular disease • cardiac pathosis (MI, AF)

  46. Factors (increased risk for stroke) • Occurrence of TIAs • Hypertension • DM • Elevated blood lipid levels • Antiphospholipid antibodies • Black male • Previous stroke • Cardiac abnormalities • Atherosclerosis • Elevated hematocrit level • Increasing age

  47. Pathophysiology • Pathologic change from : infarction intracerebral hemorrhage subarachnoidal hemorrhage

  48. Infarction • Cause : atherosclerotic thrombi or emboli of cardiac origin • Extent of infarction : site of occlusion, size of occluded vessel, duration of occlusion, collateral circulation • Neurologic abnormalities : artery involved

  49. Intracerebral hemorrhage • Cause : hypertensive atherosclerosis microaneurysms of arterioles Rupture

  50. Subarachnoid hemorrhage • Cause : rupture of a aneurysm at the bifurcation of a major cerebral artery

More Related